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Cláudia C. Oliveira and Thorbald van Hall*
Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands
The well described conventional antigen-processing pathway is accountable for most
peptides that end up in MHC class I molecules at the cell surface. These peptides
experienced liberation by the proteasome and transport by the peptide transporter
TAP. However, there are multiple roads that lead to Rome, illustrated by the increasing
number of alternative processing pathways that have been reported during last years.
Interestingly, TAP-deficient individuals do not succumb to viral infections, suggesting that
CD8 T cell immunity is sufficiently supported by alternative TAP-independent processing
pathways. To date, a diversity of viral and endogenous TAP-independent peptides have
been identified in the grooves of different MHC class I alleles. Some of these peptides
are not displayed by normal TAP-positive cells and we therefore called them TEIPP,
for “T-cell epitopes associated with impaired peptide processing.” TEIPPs are hidden
self-antigens, are derived from normal housekeeping proteins, and are processed via
unconventional processing pathways. Per definition, TEIPPs are presented via TAP-
independent pathways, but recent data suggest that part of this repertoire still depend
on proteasome and metalloprotease activity. An exception is the C-terminal peptide
of the endoplasmic reticulum (ER)-membrane-spanning ceramide synthase Trh4 that
is surprisingly liberated by the signal peptide peptidase (SPP), the proteolytic enzyme
involved in cleaving leader sequences. The intramembrane cleaving SPP is thereby
an important contributor of TAP-independent peptides. Its family members, like the
Alzheimer’s related presenilins, might contribute as well, according to our preliminary data.
Finally, alternative peptide routing is an emerging field and includes processes like the
unfolded protein response, the ER-associated degradation, and autophagy-associated
vesicular pathways. These data convince us that there is a world to be discovered in the
field of unconventional antigen processing.
Keywords: transporter associated with antigen processing, peptide loading complex, ER-associated degradation,
autophagy, CD8 T cells, T cell epitopes associated with peptide processing, tumor immunology
Classical Antigen Presentation Pathway Represents Only One
Side of the Story
Antigen-specific CD8 T-cells recognize peptides of 8–10 amino acids long that are associated with
MHC class I/β2m complexes. Cell surface expression of MHC class I/β2m/peptide complexes is
the end result of a process that begins inside the cell where proteolysis of aged, misfolded, or
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defective ribosomal product (DRiP) proteins generates small pep-
tides. Potentially, a multitude of proteolytic systems may gener-
ate antigenic peptides, but the proteasome is responsible for the
liberation of majority of them. Inhibition of proteasome activity
strongly decreased the pool of MHC class I-binding peptides
(1). Proteasomal cleavage typically creates a peptide’s C-terminus
compatible with MHC class I binding, and peptides are typically
extended at their N-terminus (2, 3). Peptides generated in the
cytosol are translocated into the endoplasmic reticulum (ER) by
the TAP1/TAP2 peptide transporter, where they have access to
the peptide loading complex (PLC), which is located within the
ER. TAP is a heterodimeric member of the ATP-binding cassette
(ABC) family of transporters, and peptide binding induces ATP
hydrolysis and transport across the ER membrane. Once in con-
tact with the PLC, the ER-amino peptidase ERAAP (also known
as ERAP1) trims N-extended peptides to a length appropriate
for MHC class I binding (4–6). Chaperone tapasin promotes the
formation of stable MHC class I/peptide complexes and acts as
an editor. Additionally, calnexin facilitates the early folding of
MHC class I heavy chains, whereas calreticulin and ERp57 are
involved in peptide loading (7–9). This pathway is also known
as the proteasome-TAP pathway and is considered as the con-
ventional processing route because it is the mainstream pathway
operating in cells under normal conditions (10–12). However,
cells are equipped with alternative routes leading to liberation
and loading of peptides into MHC class I molecules. These routes
are independent of one or more molecules from the conventional
pathway such as the proteasome, tapasin, or TAP. This has become
apparent from studies on cells with deficiencies in the conven-
tional processing pathway. In this review, we will discuss what is
known to date regarding alternative enzymes and routes to peptide
loading compartments of endogenously generated peptides that
feed the direct MHC class I pathway, especially important in
cases of failure of the conventional route. We have not included
interesting literature on cross-presentation pathways for MHC
class I peptides.
Proteasome-Independent Pathways:
Enzymes Replacing Proteasomal Activity
for Liberation of Peptides
More than 10 years ago, several papers made the important dis-
covery that a large oligopeptidase, called tripeptidyl peptidase II
(TPPII), participates in endoproteolytic activity in the cytosol and
partially compensates for a deficient proteasomal activity (13–
16). Increased TPPII activity even allowed for cell survival in
lethal conditions of proteasome inhibition (14, 16). In these con-
ditions, TPPII activity also partially restored peptide presentation
in MHC class I molecules and it was speculated that it could
account for the generation of some epitopes independently or
in cooperation with the proteasome (16). In fact, a paper from
Seifert et al. showed that TPPII was involved in the generation of
an epitope from the human immunodeficiency virus (HIV) pro-
tein negative factor (Nef) (17). After that, an increasing number
of proteolytic enzymes have been implicated in the generation
of peptide-epitopes independently of the proteasome. Insulin-
degrading enzyme (IDE) generates an epitope from the human
melanoma antigenMAGE-A3 (18). Thimet oligopeptidase (TOP)
and nardilysin are required for the generation of three other
clinically relevant CTL epitopes: the tumor-antigen PRAME, an
epitope from Epstein–Barr virus (EBV) protein EBNA3C, and
an epitope from the melanoma protein MART-1 (15). These
enzymes are part of an array of cytosolic endo- and exo-proteases
that complement proteasomal activity and degrade proteasome
products ultimately into amino acids. Importantly, the process of
peptide liberation from the protein context is inevitably coupled
to the destruction pathway and all proteases mentioned above
also destroy some antigenic peptides (19–22). Peptides that are
“rescued” from total destruction are transported by TAP into the
ER and can potentially bind MHC class I molecules.
Leader Sequences are Liberated by Signal
Peptidase and Signal Peptide Peptidase
In eukaryotic cells, secretory and membrane proteins contain
a signal sequence essential for protein targeting to the ER,
the entrance for the secretory pathway (23, 24). These signal
sequences are typically composed of three domains: a hydropho-
bic core (h region) of 6–15 amino acids, a polar C-terminal end
(c region) with small uncharged amino acids, and a polar N-
terminal region (n region) with a positive net charge (25). After
insertion into the protein-conduction channel, signal peptides are
usually cleaved from the preprotein by signal peptidase (SP) (26).
Thereafter, signal peptides, which are small domains and trapped
in the ER membrane, can undergo intramembrane proteolysis by
cleavage within their transmembrane region by the presenilin-
type aspartic protease signal peptide peptidase (SPP) (25, 27).
Peptide ligands suitable for MHC class I binding are thought to
be generated after the intramembrane proteolysis by SPP that
promotes the release of signal peptide fragments from the ER
membrane (28, 29). The SPP-cleaved fragments in the vicinity
of the cytosol can get access to the cytosol again and be further
processed by the proteasome and transported by TAP into the
ER. Most HLA class I molecules donate their leader sequences
for binding to the non-classical HLA-E, and the cleavage of these
signal sequences is mediated by SP and SPP (30–33). These leader
peptides are even the most dominant source of peptides for HLA-
E. Proper surface expression of HLA-E prevents cytotoxic action
of natural killer cells that continuously sense the presence of
peptide/HLA-E complexes through their CD94/NKG2 receptors
(34–36). The absence of these complexes at cell surface results in
failure of interactionwithCD94/NKG2A receptors, which activate
NK cells for killing their targets.
Pioneering studies by Peter Cresswell and Victor Engelhard
in 1992 revealed that most peptides presented at the surface of
TAP-deficient cells were derived from signal sequences, specific
protein regions at the N-terminus of proteins (37, 38). Indeed,
the parts of the leader peptide within the ER membrane that are
closest to the ER lumen are released there and can get access
to MHC class I grooves independent of proteasomes or TAP
(Figure 1). After the cleavage of the transmembrane sequence by
SPP, the peptide fragments are released and can associate with
MHC class I/β2m nascent molecules. This intramembrane pro-
teolysis by SPP is thought to be important for the clearance of the
ER membrane by removing small protein remnants anchored at
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FIGURE 1 | Classical and alternative pathways for MHC class I
presentation. Cells with deficiencies in components of the MHC class I
processing pathway, such as TAP, can present a repertoire of peptides
derived from alternative processing pathways. Different “housekeeping” cell
functions such as signal peptide cleavage, protein maturation in the Golgi,
and protein/organelle disposal via autophagy can provide peptide ligands for
MHC class I loading.
the membrane rendering them susceptible for subsequent degra-
dation. The intramembrane cleavage by SPP is favored by SPP
topology that conceals the catalytic center within the plane of
the membrane. The two aspartic residues required for the pro-
teolytic activity of SPP are located within conserved (Y/F)D and
G(L/I/F)GD amino acid motifs in two adjacent transmembrane
domains (39, 40). Regarding a cleavage motif for SPP, no con-
sensus cleavage site has been described. However, SPP demon-
strates a strong preference for substrates with helix-destabilizing
residues in their transmembrane domain (41–43). Amino acids
like asparagine, serine, and cysteine disturb a perfect alfa-helical
conformation of the transmembrane domain and are therefore
referred to as “helix-bending” or “helix-breaking” residues. Signal
peptides have been shown to contain amino acids with “helix-
breaking” capacity within their h region, which critically influence
their proteolytic processing by SPP (42, 44–46). The disturbance
of the α-helix caused by these residues is thought to facilitate
intramembrane proteolysis. This and other issues would be clar-
ified with the atomic resolution of this protease but this is still
lacking due to its technical difficulties. We can have an approxi-
mation of that by looking at the crystal structure of presenilin/SPP
homologs recently published (47–50). JR1 is an SPP homolog
from the archaeon Methanoculleus marisnigri that harbors nine
transmembrane helices, similar to what is predicted for SPP, with
TMD 6 and TMD 7 containing the YD and GxGD motif, respec-
tively. The two catalytic aspartate residues are located close to
each other and approximately 8Å into the lipid membrane. Prote-
olytic activity occurs in the presence of water molecules that gain
access to the catalytic aspartates through a large cavity between
two terminal domains (48). The three-dimensional structure of
a human presenilin comprised into the γ-secretase complex has
also been described (51). For the near future, we can expect more
information on the catalytic activity of this family of proteases,
including SPP, which is definitely an important contributor of
peptides for MHC class I presentation.
Additional Functions for the Signal Peptide
Peptidase
Our recent data revealed an additional role for intramembrane
proteolysis by SPP. Regardless its name, SPP also appeared to
liberate a C-terminal peptide, independent of proteasome activ-
ity. The processing of C-terminal regions of a type II protein
inserted in the ER membrane leads to the presentation of pep-
tides independently of proteasome and TAP (52, 53). The C-
terminal region from the ceramide synthase Trh4, which is a
multiple membrane-spanning protein in the ER, contains a 9-
mer peptide-epitope that is located at the very C-terminal end
of the protein and protrudes into the lumen of the ER (53–56).
The Trh4 protein has a housekeeping function and is ubiquitously
expressed. Inhibition of SPP activity blocked the generation of
the Trh4 peptide. Experiments with mutant forms of the Trh4
protein indicated that the intramembrane cleavage by SPP occurs
at the direct upstream region of the T cell epitope within the lipid
bilayer (52). We speculated that SPP activity in the ER membrane
is sufficient to liberate the minimal C-terminal 9-mer peptide
and release of this peptide into the ER lumen. Other proteolytic
enzymes, such as amino-peptidases, were dispensable. Further
carboxy-terminal processing was not needed since the epitope is
located at the very C-terminal end of the protein. Direct release
of the liberated peptide into the ER lumen is very likely, due to
the type II transmembrane orientation of the Trh4 protein tail (N-
terminus to C-terminus orientation). The exact peptide loading
mechanism of the Trh4 membrane peptide, however, remains to
be determined.
What triggers the cleavage of Trh4 by SPP is not known
yet. In addition to its liberation function of small transmem-
brane substrates, SPP has been shown to associate with misfolded
membrane proteins in complexes where SPP is represented as a
monomer, dimer, or multimer (57). It was suggested that such
high molecular weight complexes act as chaperones to dispose of
membrane aggregates (57, 58). The role of SPP in this degradation
machinery might be to liberate such aggregates from the ER
membrane. These discoveries were based on the viral US2 and
US11 proteins, which successfully labels MHC class I molecules
in the ER for retrograde transport to push this protein back to the
cytosol for degradation by proteasomes (59, 60). Interestingly, the
SPP family member, presenilin 2, seems to be associated with this
membrane proteolysis aswell (61). Since SPP andpresenilin 2 have
opposing preference for type I and type II transmembrane orien-
tations, such a “degradome” machinery might be responsible to
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clear the ER membranes. This type of machinery is called the ER-
associated degradation (ERAD) pathway. ERAD is an ER quality
control system, which monitors the integrity of nascent or ER-
resident proteins and targets incorrectly folded or misassembled
proteins to degradation. The disposal of misfolded MHC class
I heavy chains also occurs through the ERAD pathway in the
absence of viral interference (62). Clearly, viruses take advantage
of these existing pathways and hijack them in order to evade
immune recognition by cytotoxic T cells (63, 64).
Another role for SPP in ERAD has come from a recent paper
describing the cleavage of the unfolded protein response (UPR)
regulator XBP1u by SPP (65). XBP1u is a type II membrane
protein and undergoes intramembrane cleavage within a con-
served type II TM domain while integrated in a complex con-
taining SPP, the protease Derlin-1, and the E3 ligase TRC8, which
prime SPP for XBP1u cleavage. An ectodomain shedding of SPP
substrates prior to SPP cleavage is thought to be required and
normally performed by SP in signal sequences but such cleavage
was unnecessary in the case of XBP1u, similarly to what we
have described for Trh4 (52, 65). In general, the UPR induces
a strong downregulation of MHC class I molecules at the cell
surface (66, 67).
Thus, SPP activity seems to have a direct impact on MHC
class I peptide presentation by cleavage of leader sequences from
nascent proteins and the liberation of some C-termini for MHC
class I loading. A more indirect role that impacts on MHC class
I presentation has been revealed and occurs through an ERAD
pathway. This is also supported by a recent study using a systems-
level strategy reporting the involvement of SPP in the network that
coordinates the ERAD response (68).
Liberation of Peptides in the Secretory Route:
Furin
The group of Yewdell showed more than a decade ago that pep-
tides located at the C-terminus of ER-targeted proteins are very
efficiently generated and presented on MHC class I (69–72). The
location of the peptide was essential to be at the very end of the
C-terminus of the protein, not requiring C-terminal trimming, in
line with the fact that there is poor carboxypeptidase activity in
the ER (73). They described the presentation of TAP-independent
peptides from one ER-resident protein, Jaw1, and proteins in the
secretory pathway, like ovalbumin and CD23. In each case, the
peptides were efficiently liberated from the very C-terminus by
the activity of yet unidentified endo-proteases to be generated as
class I ligands. Based on this pathway of peptide liberation, the
authors provided the term “C-end rule” to highlight the capacity
of ER-resident proteases to liberate class I ligands from the C-
terminal ends of ER-targeted proteins. The liberation of peptides
without the intervention of the proteasome can also occur in
the trans-Golgi network (74, 75). The main proteolytic enzyme
involved was shown to be furin, a known protease of the trans-
Golgi network normally required for the maturation of secreted
proteins (e.g., growth factors andneurotransmitters) by cleaving at
precise stretches of three to four basic residues (76). Furin is part of
a family of proprotein convertases that comprises nine members
(77). Three members (PC5/6, PACE4, and PC7) including furin
are widely expressed and together they take part in a variety of
processes occurring in the trans-Golgi network, cell surface, or
endosomes. This leads to the activation or inactivation of recep-
tors, ligands, enzymes, viral glycoproteins, or growth factors (78).
Furin also has important functions during development by pro-
cessing substrates like bone morphogenetic protein 10 (BMP10),
a member of the TGF-β superfamily that plays a critical role
in heart development (79). Furin processes a wide variety of
precursor proteins after the C-terminal arginine residue in the
preferred consensus motif –Arg–X–Arg/Lys–Arg#–X– (X is any
amino acid and “#” indicates the cleavage position) (80). Initially,
this pathway was studied with the use of a model peptide at the C-
terminus of the secreted Hepatitis HBe protein. Furin-processed
antigens targeted to the secretory route were presented by MHC
class I at the cell surface and could elicit functional CD8 T-cell
responses in vivo in a TAP-independent fashion (75, 81). The C-
termini of secretory or ER-localized proteins thus appear to be
processed for presentation to CD8 T cells (Figure 1).
TAP-Independent Pathways: Alternative
Routing to MHC Class I Loading
Compartments
The generation of MHC class I ligands described above defines
several alternative ways to generate peptide ligands without the
intervention of the proteasome. These represent unusual pathways
for peptide generation. Now, we will discuss a different constraint
in the conventional antigen presentation pathway related to the
blockade of peptide entrance in the ER due to TAP deficiency. In
human beings, TAP-deficiency syndrome has been described in
several independent families and results from mutations in either
one of the subunits of the peptide transporter, TAP1 and TAP2
(82, 83). Interestingly, these TAP-deficient individuals do not
succumb to viral infections, suggesting that CD8 T cell immunity
is sufficiently supported by alternative TAP-independent process-
ing pathways. To date, a diversity of viral and endogenous TAP-
independent peptides have been identified in the grooves of differ-
ent MCH class I alleles. Importantly, these TAP-deficient patients
harbor a polyclonal CD8 T-cell repertoire that is capable of recog-
nizing peptides from the EBV virus, like protein LMP2, presented
on TAP-deficient cells (84). The TAP-independent processing
pathway is capable of generating enough MHC class I/peptide
complexes in order to keep immunosurveillance and control of
viral infections. Studies with TAP1-knockout mice have shown
that surface expression levels of MHC class I are indeed lower,
but the remaining complexes do induce a broad and polyclonal
repertoire of CD8 T-cells (85–87). The TCR usage was shown to
be very comparable to that of wild-type mice and TAP1-knockout
mice were capable of mounting anti-viral CD8 T cell responses.
Together, these data show that, although crippled, the MHC class
I-presented peptide repertoire in the absence of TAP is sufficient
to support CD8 T cell immunity.
TAP-Independent T Cell Epitopes: TEIPP
Interestingly, peptides emerging from alternative TAP-
independent routes appeared to be immunogenic. Following
immunizations in mice with TAP-deficient tumor cells, specific
CD8 T-cells were induced that recognize TAP-deficient cells, but
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not normal cells (56, 88). These T-cell epitopes seemed to be
selectively presented by TAP-deficient cells but not under normal
conditions. This alternative peptide repertoire emerges due to
processing defects and therefore these peptides were named “T
cell epitopes associated with impaired peptide processing” (TEIPP).
The molecular identification of some TEIPP peptides revealed
that they can be diverse in length (from 9-mer to 18-mer),
amino acid composition, and MHC class I binding, as some
are presented by classical MHC class I molecules and others
by the non-classical MHC molecule HLA-E and the mouse
homolog Qa-1b (Table 1) (35, 89–92). They are derived from
normal housekeeping proteins with ubiquitous expression, but
are surprisingly not loaded on MHC class I in cells with an
intact antigen-processing machinery. They constitute normal
self-peptides (non-mutated, not pathogen- or tumor-specific)
and can be regarded as real neo-antigens. The immunogenicity of
TEIPP peptides exists because they are not presented by normal
cells including the thymus. During thymic development, T cells
are subjected to two subsequent processes called positive and
negative selection (93, 94). Negative selection is necessary for
the maintenance of self-tolerance as it induces the deletion or
inactivation of potentially autoreactive thymocytes (95). We
recently demonstrated that TEIPP-specific CD8 T-cells indeed
do not undergo negative selection and are thereby available
for therapeutic exploitation. Since the peptides recognized by
TEIPP-specific CTL are derived from housekeeping proteins, we
tried to understand why TEIPPs are not presented by processing
intact cells.
Collectively, our data show that TEIPP peptides are actually
produced within processing proficient cells, but somehow are
not or not sufficiently presented by their surface MHC class I
molecules. Taking the Trh4-derived TEIPP peptide as a model, we
have analyzed the expression of the Trh4 gene in several epithelial
populations isolated from wild-type and TAP1-ko mice (53). This
analysis revealed the same level of RNA transcripts between the
normal and knockout populations, suggesting comparable protein
levels in both cell types. The liberation of the Trh4 peptide is
performed by SPP, which is active in TAP-positive as well as
TAP-negative targets (52). Overexpression of the Trh4 gene in
TAP-positive cells leads to surface presentation in MHC class I
(53), still in a proteasome-independent way. Moreover, protea-
some inhibition in TAP-positive cells results in presentation of
the endogenous Trh4 peptide (56), indicating that, indeed, this
TEIPP peptide is generated in all cells but loses competition with
the overwhelming amount of TAP-imported peptides in TAP-
positive cells. Some alternative peptides, like the ones derived
from EBV proteins were shown to be presented on TAP-positive
cells to comparable extent, although using alternative pathways.
Moreover, our data suggest that the limited quantity of the Trh4
peptide-epitope in the ER is the main cause of selective presen-
tation in TAP-deficient cells. Interestingly, gradual increase of
overexpression correlated with the degree of recognition by the
TEIPP-specific CTL clone, implying that TAP transport actually
constitutes a strong barrier for TEIPP peptides. The study of
humanTEIPP antigens corroborates these findings. One antigenic
peptide is encoded by the human CALCA gene and derives from
the signal sequence of preprocalcitonin (ppCT) protein. This
peptide is liberated in the ER lumen by sequential cleavage with
SP and SPP, independently from proteasomes (Table 1) (96). The
presentation of the ppCT peptide to specific CTL was found in
human lung and medullary thyroid carcinomas that had very low
expression of TAP. Presentation of the ppCT peptide occurred
also in normal non-transformed cells, such as dendritic cells
(DCs), after knockdown of TAP. Overexpression of the CALCA
gene in DCs and TAP-positive tumor cells resulted in recogni-
tion by the specific CTL clone (97). Identification of additional
human TEIPP antigens at the molecular level will enable CD8
T cell targeting of otherwise CTL-resistance TAP-negative tumor
variants (98, 99). Together, these findings support the model of
peptide competition in the ER as a factor that prevents presenta-
tion of peptides from alternative sources, and shape a picture of
alternative processing pathways that emerge upon defects in the
conventional one (Figure 1).
How to Reach Peptide Loading Complexes When
You Bypass TAP?
The precise loading mechanism of TAP-independent signal pep-
tides into MHC class I molecules is not known, since processing
by SP and SPP is thought to take place outside of the PLC.
This sophisticated machinery for optimizing ligand length and
quality and facilitating peptide loading onto nascent MHC class
I molecules greatly facilitates peptide loading by physical bridging
transporters to chaperones for loading and also “edits” the reper-
toire of bound peptides to maximize their affinity (7). The PLC
molecule tapasin tethers MHC class I molecules to the peptide
transporter acting together with the chaperone calreticulin and
TABLE 1 | TEIPP peptide-epitopes defined thus far based on CD8 T-cell recognition.
Peptide sequence/MHC class I Source protein Location in protein Responsible enzyme Presented upon Reference
MCLRMTAVM H2-Db Trh4 Q9D6K9 (1) C-terminal SPP (2) TAP deficiency (53)
“mi3 epitope” H2-Kb Unknown Unknown Proteasome TAP deficiency (119)
FAPLPRLPTL Qa-1b (3) Acyl carrier protein Q9CR21 N-terminal Unknown TAP deficiency (91)
FYAEATPML Qa-1b Fam49b “hypothetical protein”
NM_144846
Central Unknown ERAAP (4) deficiency (92)
VLLQAGSLHA HLA-A2*0201 Preprocalcitonin P01258 Signal sequence SP (5) and SPP TAP deficiency (97)
(1) UniProtKB database.
(2) SPP is signal peptide peptidase.
(3) Qa-1b is the mouse homolog of HLA-E.
(4) ERAAP is ER-amino-peptidase.
(5) SP is signal peptidase.
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the oxidoreductase ERp57 (100). Tapasin can sense the quality of
peptide bound by MHC class I complexes, and allows successive
rounds of peptide binding until a certain affinity threshold is
met. Trimming of incoming peptides by ERAAP can be neces-
sary for obtaining a good peptide length before selection by a
defined MHC class I allele. A recent paper states that MHC class I
molecules initially bind a variety of peptides, including some low-
affinity or N-terminally extended ones but then quickly dissociate
from themolecule followed by the selection of the best fitting can-
didates (101). However, TAP-independent leader peptides do not
arrive in the ERviaTAPand thus lack these editing andoptimizing
chaperones. In the absence of TAP transporters, the loading of
peptides into MHC class I occurs without a fully functional PLC
at hand. In that respect, inefficient loading of leader peptides in
TAP-positive cells can be expected, whereas in cells devoid of
TAP, this alternative ER entrance mechanism allows emergence
of these peptides. So here, the PLC floats in the ERmembrane and
is dispatched from the entry site of peptides. Indeed, differential
mass spectrometry analysis showed an enhanced presentation
of leader peptides in cells lacking the peptide transporter (102).
After all, MHC class I molecules get loaded with the available
repertoire: from conventional or unconventional sources. But how
do these “untapped” peptides find their way to empty MHC class
I molecules at all? It has been shown that loading of peptides
in MHC class I can occur with the minimal components of
tapasin–ERp57–MHC class I complexes (103), but we have to
assume that the chances of a peptide to find the PLCmachinery in
the ER are scarce. On the other hand, TAP-deficient cells harbor
more peptide-receptive class I molecules compared to normal
cells (104). These peptides might actually be actively chaperoned
toward these open grooves. Chaperoneswith high peptide binding
capacity in the ER are heat shock proteins (e.g., HSP96) and
PDI, an isomerase that efficiently binds free peptide (105). It is
possible that TAP-independent peptides are captured by these
molecules and chaperoned toMHC class I. Recent studies suggest
that the TAPBPR molecule (“Tapasin-like”) binds those MHC
class I proteins that are not bound to tapasin in the PLC, so we
might hypothesize that this pool of peptide-receptive groovesmay
function to load leader peptides (106). However, this still needs to
be investigated.
Other ways to access peptide-receptive MHC has been pro-
posed and are related to the intracellular traffic of hydrophobic
peptides. Studies with several epitopes from the LMP2 protein of
the EBV showed that peptides, which possess a high hydropho-
bicity index, were presented in a TAP-independent manner (107).
The proposed mechanism describes the generation of these pep-
tides outside the ER, since proteasome activity is needed for
presentation, and subsequently free diffusion across the ERmem-
brane possible due to their high hydrophobicity. These peptides
might transgress membranes spontaneously or via alternative
membrane transporters.
Autophagy: MHC Class I Peptide Loading in
Vesicular Compartments
A recent study by Tey et al. showed that the processing of a pep-
tide antigen from the human cytomegalovirus (HCMV) latency
associated protein, pUL138, occurs entirely in the vesicular path-
way and is mediated by autophagy (108). Also other examples
of autophagy enhanced MHC class I presentation of viral anti-
gens were reported (109, 110). During autophagy, large portions
of cytoplasmic content, including proteins and organelles, are
encapsulated in doublemembrane vesicles called autophagosomes
(111–114). The autophagosomal membrane has been proposed
to originate from the ER (115, 116) and peptide-receptive MHC
class I molecules might be present in autophagosomes, allowing
for loading of peptides in these vesicular compartments (117).
In addition, recirculating MHC class I molecules from the cell
membrane end up in endosomes and can have contact with
autophagosomes before returning to the endocytic network. Tran-
sit for membrane-associated proteins between autophagosomes
and endosomes has been observed by live cell imaging (118).
Moreover, peptides generated by the proteasome seem to get
access to the endocytic vesicular pathway as well. We recently
found at least one example for this in our TEIPP repertoire
FIGURE 2 | Peptides presented on MHC class I molecules in normal and
TAP-deficient cells derive from different MHC class I processing
pathways. Peptides derived from each pathway are combined in different
proportions and combinations. The MHC class I peptide repertoire can therefore
be compared to a painter’s palette where the different “colors” (peptides) are
mixed and used to create a colorful and complex “picture.”
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that is generated by the proteasome but is TAP-independently
presented (Table 1) (119). The presentation of this peptide was
surprisingly enhanced by blockade of the proton pump in endo-
somes, indicating that this antigenmost likely crosses the vesicular
pathway (119). Finally, mass spectrometry analysis of the TAP-
independent peptide repertoire pointed at proteins located in
the vesicular compartment as an important source (120–122).
Though these alternative processing and loading compartments
have not fully been unraveled, these data strongly support the
notion that the vesicular pathway and autophagy contributes to
antigen presentation by MHC class I molecules.
In Conclusion
On summarizing, we can conclude that, even though the con-
ventional proteasome-TAP pathway represents the major source
of the MHC class I peptide repertoire, alternative processing
pathways clearly complement the total pool. This multitude of
MHC class I processing pathways can be compared to a colorful
palette where the painter combines the different colors that will
end up in different proportions and combinations in the final
picture (Figure 2). In situations of viral infections, cellular trans-
formation, or other initiators of stress, the contribution of these
alternative pathways might gain importance. The SPP and maybe
their family members are convincing examples of alternative pro-
teolytic systems that feed the alternative routes of antigen presen-
tation. The precise molecular identification of alternative load-
ing mechanisms unto peptide-receptive MHC class I molecules,
whether it be in the ER or in autophagosomes, still needs in-
depth investigation. In that respect, peptides can walk onmultiple
different paths before ending up in the grooves ofMHC class I and
therefore illustrate the old expression that multiple roads lead to
Rome.
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